Bellerophon Therapeutics, Inc. (BLPH) Downgraded by Zacks Investment Research to Hold
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “
A number of other brokerages also recently commented on BLPH. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Bellerophon Therapeutics in a research report on Wednesday, September 6th. ValuEngine downgraded Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 10th.
Shares of Bellerophon Therapeutics (NASDAQ:BLPH) traded down 0.96% on Thursday, hitting $1.03. The stock had a trading volume of 593,144 shares. The company has a 50-day moving average of $1.14 and a 200 day moving average of $1.29. Bellerophon Therapeutics has a 52 week low of $0.43 and a 52 week high of $1.69. The company’s market capitalization is $36.58 million.
Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03. On average, equities research analysts predict that Bellerophon Therapeutics will post ($1.12) EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/14/bellerophon-therapeutics-inc-blph-downgraded-by-zacks-investment-research-to-hold.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Susquehanna International Group LLP bought a new position in Bellerophon Therapeutics during the second quarter valued at $1,316,000. Vanguard Group Inc. grew its holdings in Bellerophon Therapeutics by 52.6% during the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after purchasing an additional 211,111 shares during the period. Goldman Sachs Group Inc. bought a new position in Bellerophon Therapeutics during the first quarter valued at $125,000. Finally, Renaissance Technologies LLC grew its holdings in Bellerophon Therapeutics by 99.7% during the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock valued at $711,000 after purchasing an additional 238,300 shares during the period. 45.85% of the stock is owned by institutional investors and hedge funds.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.